Compare TV & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TV | FTRE |
|---|---|---|
| Founded | 1969 | 1996 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 1993 | N/A |
| Metric | TV | FTRE |
|---|---|---|
| Price | $3.36 | $17.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | $4.93 | ★ $15.50 |
| AVG Volume (30 Days) | 1.2M | ★ 1.2M |
| Earning Date | 02-20-2026 | 03-02-2026 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,246,959,081.00 | $2,759,900,000.00 |
| Revenue This Year | N/A | $3.21 |
| Revenue Next Year | N/A | $0.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.88 |
| 52 Week Low | $1.55 | $3.97 |
| 52 Week High | $3.48 | $18.82 |
| Indicator | TV | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 68.89 | 54.55 |
| Support Level | $2.96 | $15.37 |
| Resistance Level | $3.48 | $17.81 |
| Average True Range (ATR) | 0.11 | 1.15 |
| MACD | 0.04 | -0.18 |
| Stochastic Oscillator | 80.00 | 52.12 |
Televisa is one of the leading telecommunication firms in Mexico. Its cable arm, Izzi, holds networks that pass 20 million Mexican homes and provide broadband service to nearly 6 million customers. The firm is also one of the largest pay-television providers in Mexico, with 4 million customers. Televisa owns Sky Mexico, the country's only satellite-TV provider, serving about 5 million customers. After merging its traditional media business into Univision, Grupo Televisa owns a 43% stake in combined entity TelevisaUnivision. Grupo Televisa spun off several smaller businesses, including magazine publishing, three of Mexico's professional soccer teams, and Azteca Stadium in February 2024, under the name Ollamani.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.